Immunoglobulin News and Research

RSS

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Researchers in the United States have provided important insights into the antigen-specific cellular response and evolving humoral (antibody) response to messenger RNA- (mRNA) based vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

29 Jul 2021

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

Increasing knowledge about genomic biomarkers has facilitated better monitoring and personalized management of patients with B-cell malignant tumors.

29 Jul 2021

Immunity to SARS-CoV-2 in renal transplant and dialysis patients using Pfizer/BioNTech and Moderna vaccines

A study analyzes the immune responses of medical personnel, as well as immunocompromised DP and immunosuppressed KTR patients.

27 Jul 2021

SARS-CoV-2 spike-specific antibodies induced in breast milk by COVID-19 vaccines

An interesting new paper examines how these vaccines can help young patient populations to withstand the virus.

27 Jul 2021

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

A new study describes how immunocompromised vaccine recipients may not always respond as expected to the COVID-19 vaccine.

27 Jul 2021

SARS-CoV-2 antibodies in breast milk: Study

A new study published on the medRxiv* preprint server explores the presence of immunoglobulin (Ig) antibodies IgA and IgG against SARS-CoV-2 in breast milk secreted by women with confirmed infection. The scientists also delineated the specific antigens targeted by the antibodies.

26 Jul 2021

Advantages and challenges of intranasal vaccines to fight against COVID-19 infections

There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., and Troy Randall, Ph.D., write in a viewpoint article in the journal Science.

23 Jul 2021

Efficacy of mRNA vaccine-induced memory B cells against SARS-CoV-2 variants

A new study characterizes the functional humoral immunity post-COVID-19 mRNA-based vaccination.

22 Jul 2021

Can prior human seasonal coronavirus antibody response patterns predict SARS-CoV-2 inhibition?

A new study, recently released as a preprint on the medRxiv* server, reports the intriguing finding that the cross-neutralizing antibodies elicited by human seasonal coronaviruses (sCoVs) show varying ability to prevent binding between the SARS-CoV-2 spike antigen and its cognate receptor, the angiotensin-converting enzyme 2 (ACE2).

22 Jul 2021

IgA deficiency results in substantial intestinal inflammation, study reveals

While researchers have known for years that immunoglobulin A (IgA) is important for gut health, it has remained unclear exactly what role it plays in preventing infection and disease. But now, researchers from Japan have found that eliminating IgA disrupts the balance of the intestinal ecosystem, making it susceptible to disease.

20 Jul 2021

Study reports on COVID-19 vaccine uptake and antibody prevalence in England during May 2021

A new study reports this finding, along with varying antibody prevalence among different groups and regions and between different age groups. In the current paper, available as a preprint on the medRxiv* server, the results of the sixth round of the REACT-2 study are reported.

20 Jul 2021

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Researchers in the United States have conducted a study suggesting that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit better neutralizing activity against variants of concern following vaccination against coronavirus disease 2019 (COVID-19) than previously uninfected vaccinees.

19 Jul 2021

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Researchers in Finland have conducted a study showing that the neutralizing bodies generated following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – generally persist for at least a year.

19 Jul 2021

Thai study looks at CoronaVac vaccine vs. natural immunity to SARS-COV-2 variants

A new study evaluates the efficacy of vaccine- and infection-induced antibodies against SARS-CoV-2 variants.

19 Jul 2021

Researchers discover major metabolite involved in regulating intestinal bacteria

Researchers at the RIKEN Center for Integrative Medical Sciences (IMS) have discovered that acetate, a major metabolite produced by some intestinal bacteria, is involved in regulating other intestinal bacteria.

19 Jul 2021

Oxygen therapy may improve hypoxia-induced B cell abnormalities in COVID-19

Researchers in the United States have demonstrated early and persistent B cell abnormalities in patients with moderate or severe coronavirus disease 2019 (COVID-19) that may be largely driven by hypoxia.

18 Jul 2021

How do immunocompromised patients respond to COVID-19 vaccines?

The COVID-19 vaccines produce a boost in antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, new research suggests vaccine responses aren’t all created equal. Their findings showed that immunocompromised patients, such as transplant recipients, with no prior exposure to SARS-CoV-2 produce little to no neutralizing antibodies.

18 Jul 2021

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A new study published in Vaccine assesses the safety and efficacy of the synthetic DNA vaccine candidate INO-4800, delivered as a single or double dose regime.

18 Jul 2021

Mixing COVID vaccines generates a comparable immune response

The validity and safety of mixing first and second doses of different types are explored in a paper recently uploaded to the preprint server medRxiv* by Rose et al. (July 13th, 2021), finding that robust antibody response is induced, comparable to, and perhaps even exceed that generated by homologous dosing.

16 Jul 2021

Heart problems in kids with MIS-C resolve rapidly, study shows

Heart problems in children hospitalized with multisystem inflammatory syndrome (MIS-C)--an inflammatory condition triggered by COVID--were mostly gone within a few months, a new study by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian has found.

15 Jul 2021

Immunoglobulin News and Research

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

Immunity to SARS-CoV-2 in renal transplant and dialysis patients using Pfizer/BioNTech and Moderna vaccines

SARS-CoV-2 spike-specific antibodies induced in breast milk by COVID-19 vaccines

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

SARS-CoV-2 antibodies in breast milk: Study

Advantages and challenges of intranasal vaccines to fight against COVID-19 infections

Efficacy of mRNA vaccine-induced memory B cells against SARS-CoV-2 variants

Can prior human seasonal coronavirus antibody response patterns predict SARS-CoV-2 inhibition?

IgA deficiency results in substantial intestinal inflammation, study reveals

Study reports on COVID-19 vaccine uptake and antibody prevalence in England during May 2021

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Thai study looks at CoronaVac vaccine vs. natural immunity to SARS-COV-2 variants

Researchers discover major metabolite involved in regulating intestinal bacteria

Oxygen therapy may improve hypoxia-induced B cell abnormalities in COVID-19

How do immunocompromised patients respond to COVID-19 vaccines?

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

Mixing COVID vaccines generates a comparable immune response

Heart problems in kids with MIS-C resolve rapidly, study shows

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News